AG
STRO icon

Algert Global’s Sutro Biopharma STRO Stock Holding History

Algert Global’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,283
Closed -$38K – 1565
2024
Q2 		$38K Sell
1,283
-1,093
-46% -$43.2K ﹤0.01% 1456
2024
Q1 		$134K Buy
+2,376
New +$105K 0.01% 995
2023
Q3 		– Sell
-1,225
Closed -$57K – 1249
2023
Q2 		$57K Sell
1,225
-3,329
-73% -$166K ﹤0.01% 1055
2023
Q1 		$210K Buy
+4,554
New +$289K 0.01% 1021
2022
Q2 		– Sell
-2,219
Closed -$182K – 1375
2022
Q1 		$182K Sell
2,219
-807
-27% -$76.8K 0.01% 1062
2021
Q4 		$450K Sell
3,026
-389
-11% -$69.7K 0.06% 578
2021
Q3 		$645K Buy
3,415
+1,160
+51% +$221K 0.09% 430
2021
Q2 		$419K Sell
2,255
-2,324
-51% -$455K 0.14% 209
2021
Q1 		$1.04M Sell
4,579
-1,846
-29% -$438K 0.33% 104
2020
Q4 		$1.4M Buy
+6,425
New +$1.06M 0.4% 80

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Algert Global's STRO Position: Q3 2024 in Review

Algert Global sold out of Sutro Biopharma (STRO) in Q3 2024, closing a stake of 1,283 shares — an estimated $38K sold.

Algert Global first reported a position in STRO in Q4 2020 and held it in 10 quarters. The position peaked at $1.4M in Q4 2020. 130 funds tracked by Wall St. Rank hold STRO as of Q3 2024.

  • Algert Global reported no remaining Sutro Biopharma position as of Q3 2024 after selling out during the quarter.
  • Algert Global sold 1,283 Sutro Biopharma shares in Q3 2024, an estimated $38K.
  • Algert Global first reported a position in Sutro Biopharma in Q4 2020 and held it in 10 quarters.
  • Algert Global's Sutro Biopharma position peaked at $1.4M in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2024.

Based on Algert Global's 13F filing for Q3 2024, filed 12 Nov 2024.